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INTRODUCTION
Japan Soc. of Hepatology published a “Liver cancer
white paper” in 1999. It reported that the whole
aspect of hepatocellular carcinoma (HCC) in Japan
has been significantly clarified during the past sev-
eral decades, and in the future, to develop the pro-
motion of HCC eradication is urgently needed (1).
However, with regard to the treatment of HCC, the
therapeutic modalities have diversified with the
clarification of the characteristics of HCC, and the
indication of surgical treatment (liver resection) for
HCC have also changed (2).
In this paper, the treatment outcome of HCC at
First Department of Surgery, The University of
Tokushima School of Medicine was mainly de-
scribed, with referrence to the national primary
liver cancer follow up survey report (National Re-
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port) of the Liver Cancer Study Group of Japan,
which indicated the problems associated with liver
resection for HCC.
ABBREVIATIONSANDSTATISTICALANALYSIS
The abbreviations and the definitions (tumor
staging, clinical stage, operative curability etc.) used
here were based on the General Rules for the
Clinical and Pathological Study of Primary Liver
Cancer by the Liver Cancer Study Group of Japan
(3). Statistical analysis was carried out using Stu-
dent’s t test for unpaired observations. Cumulative
survival rates and curves were calculated using the
Kaplan-Meier method. The log-rank test was used
to compare the survival curves. P-values less than
0.05 were considered statistically significant.
I. Characteristics and the problem of HCC in Japan
Over 95% of HCC in Japan is associated with
chronic liver disease (i.e. chronic hepatitis, liver
cirrhosis) by persistent infection of hepatitis B virus
(HBV) or hepatitis C virus (HCV), and develop-
ment in the liver is considered to be multicentric.
In recent years, over 80% of cases were related in
HCV (1). In the treatment, the high recurrence rate
after treatment has become a serious problem.
When it was reported in the 13th National Report,
the recurrence rate within the 2 years investiga-
tion period was 27.5%, and 85.7% of those recurring
within 1 year after treatment. The recurrence site
was a remnant liver in 84.6% of cases (4).
This has become a problem even for liver trans-
plantations for HCC in Europe and the United States
of America. In the liver transplantations of 422 HCC
patients was observed in the 1998 Registry Report,
that the cumulative survival rates were 72.2% after
1 year, 63.4% after 2 years, 47.4% after 4 years, 44.4%
after 5 years, and the recurrence rate was reported
as 25.6% (108 of 422 patients) (5). Thus, because of
the high recurrence rate after transplantation and
the poor prognosis compared with the findings of
liver transplantation for other diseases, the indica-
tions of liver transplantation for HCC have also been
discussed.
II. Changes to the therapeutic modality for HCC
In the 13th National Report (1998), liver resection
(Hr), transcatheter arterial embolization (TAE),
Chemo-Lipiodolization (Chemo-Lp), Chemotherapy
(Chemo), ethanol injection therapy (EIT),Microwave
coagulative necrosis therapy (MCT) were all used
as a therapy (4). The performed rates for HCC were
Hr : 28.6%, TAE : 46.2%, Chemo-Lp : 60.0%, Chemo :
11.3%, EIT : 24.2% and MCT : 3.1%. The proportion
of MCT in these modalities has doubled since the
12th National Report (1996) (6). Although it was
11.8% on EIT in the 10th National Report (1992)
(7), it has greatly increased to 24.2% in the 13th
National Report.
In addition, liver resection was carried out at 34.4%
in the 12th National Report (1996) (6), but in the
13th National Report (4), it had decreased to 28.6%
despite the increase in the number of registered
patients. Also, in our department, the number of liver
resections for HCC has decreased year by year since
the peak year 1993 (Fig. 1a). The features of HCC
themselves which refers to surgery have also changed.
The cases of our department were examined by
dividing into prophase (before 1993, number of patients
(n)=88) and later stages (after 1994, n=93). In the
latter stage, tumor stage IV-A increased to 30.4%,
and stage I decreased to 5.4% (Fig. 1b). That is to
say, advanced HCC over 5 cm in diameter and with
multiple nodules had increased. As a result, cases
which required lobectomy (Hr2) also increased to
27.3%. Cases in which curative resection was pos-
sible decreased, and the proportion of non-curative
resections increased. Differences appeared in the
survival rate for tumors treated like this, the latter
stage showed a poor cumulative survival rate (p=
0.1169) and disease-free survival rate (p=0.0037).
III. Results and indications for surgical treatment
for HCC
1) The outcome of HCC patients treated surgi-
cally in our department
 Survival rate and cause of death
A total of 181 patients underwent liver resection
for HCC between January, 1985 and December, 1999
at our department. The cumulative survival rate of
all cases were 77.3% after 1 year, 57.8% after 3 years,
40.4% after 5 years, 36.0% after 7 years, 9.1% after
10 years, and the disease-free survival rates were
60.0% after 1 year, 29.8% after 3 years, 24.2% after 5
years, 10.3% after 7 years and 10.3% after 10 years.
The operative mortality rate was 2.2% (4 patients).
At the time of analysis, 102 patients had died : 64
(62.7%) died because of their tumors, 29 (28.4%) died
due to liver failure, 3 died due to infection and 6 died
by other causes. In the 13th National Report (4), the
cumulative survival rate of all cases who underwent
Hr (n=16728, 1978-1995) were 83.2% after 1 year,
62.6% after 3 years, 45.3% after 5 years and 21.2%
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after 10 years, and the operative mortality rate was
1.5%. In addition, the cumulative survival rate in
patients treated by EIT (n=2080, 1988-1995) were
90.2% after 1 year, 63.1% after 3 years, 40.8% after 5
years, and in patients who underwent TAE were
60.4% after 1 year, 26.1% after 3 years, 13.3% after 5
years and 3.5% after 10 years .
Survival based on tumor size
In comparison of tumor diameters 2 cm or less
(n=31) and 2 cm to 3 cm (n=50), the patients profiles
and features of HCC did not differ between them,
and there was no significant difference in cumulative
survival rate and disease-free survival rate. Therefore,
all cases (n=177) were divided into three groups ;
small-sized HCC (tumor size≦3.0 cm, n=81), middle-sized
HCC (3.0<tumor size≦5.0 cm, n=54), and large-sized
HCC (tumor size>5.0 cm, n=42).
Cumulative survival rates at 3 cm or less in di-
ameter were 86.2% after 1 year, 66.7% after 3 years,
48.9% after 5 years, 41.8% after 7 years, and there
was no difference between the 3 cm to 5 cm groups ;
81.3% after 1 year, 67.6% after 3 years, 46.6% after 5
years, 46.6% after 7 years. However, the disease-free
survival rate of 3 cm or less were 63.4% after 1 year,
28.2% after 3 years, 20.7% after 5 years, 5.3% after 7
years, and in the 3 cm to 5 cm group, they were
77.9% after 1 year, 45.9% after 3 years, 39.9% after 5
years, 25.1% after 7 years, and in cases of 3 cm or less
it was significantly poorer (p=0.0350).
The cumulative survival rates of 5 cm and over
was 51.9% after 1 year, 25.7% after 3 years, 14.7% after
5 years, and the disease-free survival rate was 35.7%
after 1 year, 8.8% after 3 years, 8.8% after 5 years,
which were significantly poorer than the other 2
groups (p<0.0001) (Fig. 2 a, b).
Characteristics of patients with small-sized
HCC (tumor size≦3 cm)
Despite the cumulative survival rate being almost
equal between the cases of 3 cm or less and the cases
of 3 to 5 cm in our data, the disease-free survival rate
of cases of 3 cm or less was poorer than in cases of
3 to 5 cm. The reason for this was studied by com-
paring several factors influencing the survival rates
of patients and the postoperative recurrence of HCC.
As a result, the characteristics of patients with
HCC 3 cm or less were as follows (Tab. 1) ; In the
tumor-related factors, the incidence of solitary HCC
was low at 61.7% (p=0.123), and that of multicentric
HCC were high at 24.7% (p=0.0123), and well dif-
ferentiated HCC was 50.0% (0.0021). In host-related
factors, concomitant liver cirrhosis (Z2) was 65.8%
(p=0.02), indocyanine-green retention ratio at 15
min (ICGR 15) was 21.7% ± 11.3% (p=0.0030). In
hepatitis virus, no difference was recognized. In
surgery-related factors, subsegmentectomy (HrS)
or less was 88.8% (p=0.0001). However despite small
ranged liver resections, no difference was recog-
nized for intraoperative blood loss (p=0.3181). Although
the proportion of absolute curative resection was
high for 3 cm or less cases in operative curability,
Fig. 1 a Fig. 1 b
Fig.1 a. Yeary number of patients who underwent liver resection
1 b. Proprotion and comparison of tumor stage between
prophse (before 1993, n=88) and later stage
(after 1994, n=93) p=0.0077
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a. b.
Fig.2. Cumulative survival rate based on tumor size. T : tumor size n : number of patient
a. Cumulative survival rate.
survival rate of HCCs greater than 5 cm is poorer than the other 2 groups (p<0.0001).
b. Disease-free survival rate.
there are significant differences among the 3 groups (p=0.0350).
Table 1. Proprtion and comparison of patients by tumor size
Tumor size (T)
Factor T≦3.0 cm 3.0 cm < T ≦ 5.0 cm p-value
Tumor factor
well
solitary
multicentric
vp positive
50.0%
61.7%
24.7%
25.3%
20.0%
81.5%
3.0%
33.9%
0.0021
0.1230
0.0123
0.0426
Host factor
clinicalstage II + III
Z2
ICGR15
HCV positive
72.7%
65.8%
21.7±11.3%
70.3%
59.2%
43.3%
16.2±8.7%
66.7%
0.1498
0.0200
0.0030
0.4133
Operative factor
absolute non-
curative resection
blood loss
16.3%
882±801g
3.7%
1032±834g
0.0009
0.3181
Cause of death
liver failure
Recurrence
solitary
multicentric
41.8%
62.5%
28.6%
30.0%
56.6%
13.3%
0.6046
0.0585
0.1692
% : number of patients with factor/total number of each group, well : well diferrentiated HCC, multicentric : HCC of
multicentric occurrence, VP positive : tumor thrombus exists in the portal vein., Z 2 : liver cirrhosis, ICGR15:
indocyanine green retention ratio at 15 min., HCV postive : patient with HCV antibody, clinical stage and absolute
non-curative resection : criteria used The General Rules for the Clinical and Pathological Study of Primary Liver
Cancer
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the proportion of absolute non-curative resection due
to the tumor being deep in the liver, etc. was also
high at 16.3% (0.0009). For the cause of death, liver
failure was 41.8% (p=0.6046). However there was no
significant difference in intrahepatic recurrence
modes, and the incidence of the multicentric re-
currence tended to be high at 28.6% (0.1692).
As described above, in HCC of 3 cm or less, the
incidence of concomitant liver cirrhosis was high,
and the hepatic functional reserve was lowered in
the majority of cases. Accordingly, patients appeared
to have similar degrees of enforced operative load with
respect to large liver resection despite small liver
resection, and some developed deterioration of he-
patic function after surgery. It was suggested that
multicentric recurrence, in addition to metastatic
recurrence, was related in the disease-free survival
rate after surgery.
2) The indications of liver resection for HCC based
on tumor size
 Surgery for HCC with 3 cm or less
Various medical congresses have examined which
therapy is chosen for the small HCC (3 cm or less)
as a first treatment such as the 53rd Japanese Soc.
of Gastroenterological Surgery general meeting,
February, 1999 : workshop “the surgical treatment
policy for the small liver cancer”, The 35th Japan
liver cancer workshop, June, 1999 : symposium “the
treatment strategy for the small liver cancer”, and
The 3rd Japan Soc. of Hepatology : October, 1999 :
panel discussion “Re-examination of the treatment
selection in the small Hepatoma”. However a fixed
consensus has not been obtained because research
results have been equivocal. However, in the 13th
National Report (4), 80.1% of EIT was carried out
for HCC of 3 cm or less, and, 96.1% was for HCC
with less than three nodules. MCT was indicated
in similar to EIT, and 78.9% of MCT was carried out
for HCC of 3 cm or less and with less than three
nodules. Thus, it is general practice to perform EIT
and MCT for HCCs of 3 cm or less and tumor num-
bers of three or fewer.
In the results of EIT for small HCC (tumor size
≦3 cm, tumor number≦3 nodules) at the leading
2 institutes in Japan, The Univ. of Tokyo (digestive
medicine) was 47.0% after 5 years and 26% after 10
years on the cumulative survival rate (8), and they
were 54.2% after 5 years, 16% after 10 years at The
Univ. of Chiba (1st Dep. of Medicine) (9). The cu-
mulative survival rate of our cases by liver resec-
tion were 86.0% after 1 year, 66.3% after 3 years,
48.2% after 5 years, 41.2% after 7 years and 8.8%
after 10 years. The 5-year recurrence rate was 75%
in the Univ. of Tokyo, 86.1% in The Univ. of Chiba,
and 80.5% in our department. Thus, our data were
similar to the results of the 2 institutes mentioned
above (Tab. 2).
Next, the survival rate of solitary and multiple
HCCs with 3 cm or less in diameter was analyzed
in our department. The cumulative survival rate of
patients with solitary HCC was 83.5% after 1 year,
72.5% after 3 years, 61.5% after 5 years, 54.2% after
7 years and 18.1% in 10 years. In addition, that of
patients with multiple HCCs was 90.0% after 1 year,
57.3% after 3 years, 28.9% after 5 years, 19.3% after
7 years, which showed no significant difference,
although it tended to be poorer in patients with multi-
ple HCCs (p=0.1691). Furthermore, the disease-free
survival rate of solitary HCC were 74.6% after 1
year, 37.9% after 3 years, 25.6% after 5 years, 9.3%
after 7 years and 9.3% after 10 years, and those of
multiple HCCs were 47.1% after 1 year, 13.2% after
3 years, 13.2% after 5 years. The survival rate of
solitary HCC was significantly better than for multiple
HCCs (p=0.008) (Fig. 3a, b). The 5 year survival
rate of solitary HCC was better than the 41.8% for
the EIT for solitary HCC in the 13th National Report
(4), and it was also better than the 53.6% reported
at the Univ. of Chiba (9).
Ryu et al. examined the 3,225 cases of multiple
Table 2. Survival rates and recurrence rates at 5 years after EIT at the leading 2 institutions in Japan and the our findings
by liver resection for small-sized HCC (tumor size≦3 cm, tumor number≦3 nodules).
institute modality
number of
patients
survival rates recurrence
rates at 5yrs1yr 3yrs 5yrs 7yrs 10yrs
our cases Hr 181 86.0% 66.3% 48.2% 41.2% 8.8% 80.5%
Univ. of Tokyo EIT 349 93% 74% 47% 38% 26% 75%
Univ. of Chiba EIT 245 97.4% 72.0% 54.2% 34.8% 16.0% 86.1%
Univ. of Tokyo : Digestive Medicine, The University of Tokyo School of Medicine ; Univ. of Chiba : 1st Department
of Medicine, The University of Chiba School of Medicine Hr : liver resection, EIT : Ethanol injection therapy
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facilities retrospectively, and reported that resec-
tion or EIT should be performed in patients with
Clinical Stage I (CSI) disease with tumors≦3 cm
and≦3 in number, but in patients with CSII, EIT
should be performed. Since the operative mortality
rate of patients with CSII was significantly worse
than those with CSI, resection should be selected
taking the site of the tumor into consideration in
patients with CSII (10). When the survival rate was
compared by Clinical Stage in our cases, the 3-and
5-year survival rates in patients with CSI were 78.5%
and 60.4%, respectively. In patients with CSII, the
3-and 5-year survival rates were 62.2% and 51.6%
and those rates in patients with CSIII were 62.5%
and 0%, respectively. Although survival was poor
in patients with CSIII, there was no significant dif-
ference among 3 groups (p=0.2507). The 3-and 5-year
disease-free survival rates in patients with CSI were
47.9% and 35.9%, respectively. In patients with CSII,
the 3-and 5-year disease-free survival rates were 21.9%
and 15.0%, and in patients with CSIII, those rates were
12.5% and 0%, respectively. The disease-free survival
rate of patients with CSII or III was significantly worse
than that of patients with CSI (p=0.0042).
Therefore, in patients with HCC of 3 cm or less,
there is no significant difference between liver re-
section or EIT for solitary HCC. We used liver re-
section as the first selection for solitary HCC with
CS I. However, it is suggested that priority should
be given to topical treatments such as EIT or MCT
in multiple HCCs and for patients with clinical stage
II or III.
Surgery for HCC of 3 to 5 cm
In the 13th National Report (4), the cumulative
survival rate of EIT for 3 to 5 cm (n=240) were 78.5%
after 1 year, 43.3% after 3 years, 24.3% after 5 years.
The cumulative survival rate of TAE for HCC (all
cases, n=13,228) were 60.4% after 1 year, 26.1% after
3 years, 13.3% after 5 years. Beppu et al. reported that
the 3-year survival rate of HCC for 3.1-5.0 cm in di-
ameter by TAE was 49.0% (11). The our data of liver
resection for HCC of 3 to 5 cm was better than
both therapies. Especially, the survival rates of soli-
tary HCC by liver resection which were 54.7% after
5 years and 47.9% after 10 years. The disease-free sur-
vival rate was 44.0% after 5 years and 27.7% after 10
years. This showed solitary HCC was very good for
survival over long terms.
In the investigation of multiple facilities by Seki
et al., the cumulative survival rates of liver resec-
tion for a solitary HCC of 3 to 5 cm were 60.2% after
5 years, 26.4% after 10 years in patients with clini-
cal stage I. Liver resection showed good results in
comparison with TAE of the same clinical stage. Simi-
lar results were seen even in patients with clinical
stage II (12). Accordingly, HCC with 3 to 5 cm in
diameter should have liver resection as the first se-
lection, and especially a patient with solitary HCC
it is regarded as the best indication of liver resec-
tion.
Surgery for HCC of over 5 cm in diameter
The cumulative survival rates of HCC of over 5
cm by liver resection were 51.9% after 1 year, 25.7%
after 3 years and 14.7% after 5 years in our depart-
ment, and the disease-free survival rates were 25.7%
after 1 year, 8.8% after 3 years, 8.8% after 5 years.
This must be regarded as poor prognosis. Beppu
et al. reported 5-year survival rate of HCC greater
a b
Fig.3. Cumulative survival rate (a) and disease-free sruvival rate (b) of patients with solitary or multiple HCC (tumor size≦3 cm)
p = 0.0080
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than 5.1 cm in TAE of 13.1% (11). Seki et al. re-
ported that the cumulative survival rates of TAE
for over 5.0 cm was 32.7% after 3 years and 23.3%
after 5 years in a solitary HCC (12). Thus, it is un-
clear whether liver resection or TAE for HCC of
greater than 5 cm is best.
In our data of HCCs greater than 5 cm by tumor
stage, the cumulative survival rates were 50.3% after
3 years and 33.6% after 5 years in patients with tumor
stage II, and 50.0% after 3 years and 25.0% after 5
years in patients with tumor stage III, which were
comparatively good results. However, in patients
with tumor stage IV-A, the survival rate was 16.8%
after 1 year, and no patient was alive after 2 years
postoperatively (Fig. 4a). In addition, the difference
could not be seen in the survival rates by clinical
stage. When survival rate by operative curability
was observed, cumulative survival rates of relative
curative resection were 37.5% after 3 years and 18.8%
after 5 years, and those with relatively non-curative
resection were 29.0% after 3 years and 17.4% after
5 years. In absolute non-curative resections, the cu-
mulative survival rates were 12.5% after 1 year, and
no patient was alive after 2 years postoperatively
(Fig. 4b), of which 87.1% died of cancer recurrence.
The mode of recurrence was mostly metastatic
intrahepatic recurrence with distant metastasis to
lungs, bone etc.
Thus, in HCCs greater than 5 cm, liver resection
is the first choice for patients with tumor stage II
or III. However the surgical indication for patients
with tumor stage IV-A and/or a patient becoming
an absolute non-curative resection should be pru-
dent.
IV. The apporpriate liver resection with special
reference to recurrence after surgery
For recurrence after liver resection, there are two
well documented modes ; metachronous multicentric
recurrence and metastatic recurrence. In the 12th
National Report, multicentric recurrence was 8.9%
after hepatectomy. Probable multicentric recurrence
was 27.8%, metastatic recurrence was 37.6%, and in-
distinctness was 25.9% (6). In our data, recurrence
was 16.6%, which showed multicentric recurrence
histologically (13). it was clarified that most HCC
arises in chronic liver disease (i.e. liver cirrhosis)
and cancerates via a multistep process (14).There-
fore, it appears that there is a limit in pursuing the
higher radicality by only extending the extent of
liver resection as long as themetachronousmulticentric
recurrence exists after surgery. In other words, it
is only metastatic recurrence that we can be prevented
surgically.
When factors influencing the metastatic recur-
rence of HCC postoperatively were analyzed, tumor
size, portal vein invasion (Vp), hepatic vein inva-
sion (Vv), α-feto protein (AFP), and intrahepatic
metastasis (IM), cancer-related factors were mainly
related (13). So, the extent of liver resection was
examined by tumor size as an independent factor
by multivariate analysis using a stepwise forward
Cox regression model. Since the details have already
been reported (13, 15, 16), only the conclusion is
a b
Fig.4. Survival rate of patients with tumor sizes greater than 5 cm in diameter.
a : Cumulative survival rate by tumor stage
b : Cumulative survival rate by operative curability
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described here.
In HCC of 5 cm or less in diameter, it does not
always necessary to resect greater than the extent
of the tumor (Hr≧H) by curative resection ac-
cording to the General Rules for the Clinical and
Pathological Study of Primary Liver Cancer, and a
limited resection according to Glissons structure
and with a negative surgical margin (TW-) can be
performed. HCC with multiple nodules can also be
treated with limited resection as described above for
each nodule. However, an extended liver resection
in the possible range of the liver functional reserve
is required for the treatment of HCCs greater than
5 cm. Since the prognostic factor in HCCs greater
than 5 cm was not the clinical stage of patient but
rather cancer-related factors, This suggested that the
patients, in which the curative resection is possible,
should be chosen.
The extent of liver resection should be consid-
ered according to the hepatitis virus. Since patients
with hepatitis B showed a smaller decrease in liver
function, and often recurred from the primary tumor
to the remnant liver via the portal vein, systemic
resection should be offered as far as possible in the
initial operation. In contrast, because metachronous
multicentric recurrence is dominant in patients with
hepatitis C postoperatively, limited resection ac-
cording to Glissons structure should be performed
(17).
V. Challenge and limits of surgical treatment for
HCC
 HCC with tumor thrombus in the portal
vein (Vp 2, 3)
In the 13th National Report, the incidence of pa-
tients in which tumor thrombus existed in the sec-
ond branch of the portal vein (Vp2) and the first
branch, or trunk of the portal vein or in a branch
on the contralateral side (Vp3) were 3.1% and 3.3%
each (4). The number of patients with Vp2,3 togeth-
er reached 16 (8.8%) in our department. The cumu-
lative survival rates of these cases were 22.3% after
1 year, 7.4% after 3 years, 0% after 4 years, which
were significantly poorer than patients with Vp0,1
(p<0.0001). All cases with Vp 2,3 recurred approxi-
mately 1 year postoperatively, and 73.3% of the pa-
tients died of the cancer recurrence. Several major
efforts have been attempted to deal with tumor
thrombus in the portal vein by aggressive treat-
ment (18). Also in our department,, priority was
given to the dissection of the hepatic hilum prior
to the hepatic parenchymal transection, and the
portal vein tumor thrombus was removed first as a
contrivance of operative method. However, there
has been no notable improvement in the treatment
outcome. Yamaoka et al. was also reported that the
cumulative survival rates with Vp3 were 31% after
1 year, 6% after 3 years, 6% in 5 years and the prog-
nosis was equally bad even in Vp2, and there was
a limit to attempting an improvement in the treat-
ment outcome only by liver resection for the Vp2,3
cases (19). This suggested that adjuvant therapy
should be performed after surgery, although a uni-
versal and effective treatment has not yet been re-
ported.
HCC with Tumor thrombus in the Inferior
Vena Cava (IVC)
When combining the Vv3 cases (tumor throm-
bus in the IVC) with the Vv2 cases (tumor throm-
bus in the main hepatic vein, or short hepatic vein),
they were 10 cases (Vv 2 : 6 cases, Vv 3 : 4 cases).
A total of 5.5% of patients underwent liver resec-
tion in our department. There were tumor thrombi
in the right hepatic vein in 3 of 6 patients with Vv2,
which removed together with the main tumor.
However, 3 remaining cases with Vv2 and 4 cases
of patients with Vv3 required clamping of the infe-
rior vena cava (IVC) to remove the tumor throm-
bus (Tab. 3).
We used three methods for clamping the IVC.
The first method was clamping only the retrohepatic
IVC. In the cranial method, the IVC clamp was placed
on the IVC below the orifice of the hepatic vein to
the IVC and another clamp was put on the infrahepatic
IVC. It is advantageous to carry out the dissection of
the IVC without interrupting of the hepatic inflow,
such as Pringle’s maneuver. This technique was used
in cases 1,2 and 3. In case 3, the tumor invaded
the wall of IVC directly, so the retrohepatic IVC was
resected, and was replaced using Gore-Tex with a
ring.
The second method is Total Hepatic Vascular
Exclusion (THVE) (20, 21). An IVC clamp was put
on the suprahepatic and infrahepatic IVC in addi-
tion to interruption of the hepatic inflow. This pro-
cedure completely isolates the liver from the circu-
lation and primarily aims at preventing bleeding. It
was used in case 4. To shorten the hepatic ischemia
time, the liver parenchymal transection is carried
out in advance, and the dissected liver is connected
with the tumor thrombus in the IVC only by the
hepatic vein. Then the IVC is incised, and the tu-
mor thrombus in the IVC is extracted together with
the resected liver.
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The third method is for extracting the tumor throm-
bus in the IVC with the transected liver under the
extracorporeal circulation using a cardiopulmonary
bypass (22). This was done at cases 5, 6 and 7. Still,
in case 6, it was cannulated via the portal vein to
considerately lengthen the extracorporeal circulation
time, and core cooling was done using a Lactate-Ringer
solution cooled at 4℃ in addition to topical cooling.
The ischemic time of each case is shown in Table 3.
They had few ascites and pleural effusion postoperatively,
but patients left hospital without serious complica-
tions, such as liver failure.
When the outcome of patients with Vv2,3 were
observed by the existence of Vp, one case (case 6)
of 4 cases with Vp 2,3 died of another cause within
6 months postoperatively, but no patient had re-
currence. Another 2 cases (cases 3 and 4) died of
multiple liver metastasis 10 months and 7 months
after surgery, respectively. one remaining patient
(case 7) had multiple liver metastasis 2 months after
surgery, but is doing well 4 months postopratively.
One patient (case 1) of three caseswith Vp0,1 showed
lung metastasis and multiple liver metastasis 2 months
postoperatively, and died of cancer 7 months after
surgery. However, One case (case 2) of 3 cases with
Vp0,1 also recurred in the remnant liver 3 months
after surgery, but arterial injection chemotherapy of
stylene maleic acid neocarcinostatin (SMANCS) and
treatment by EIT were undertaken, and cancer
bearing survival was progress 4 years and 10 months
postoperatively. Case 5 with tumor thrombus in the
right atrium had multiple lung metastasis 1 year
and 3 month after surgery. Systemic chemothera-
py with cisplatin (CDDP) +5-fluorouracil (5FU) and
radiation were enforced, and survival at 4 years
and 7 months after surgery was obtained.
Thus, most of the patients with Vv2 or 3, had a
tumor greater than 5 cm in diameter and showed recur-
rence in lungs and/or liver after early postoperatively.
The cumulative survival rates were 57.1% after 1
year and 28.6% after 3 years, and the prognosis is
poor. However, patients with Vv2,3 showed cardiac
insufficiency, pulmonary embolism and inferior vena
caval syndrome. And, there is no other effective
method of treatment. In patients with Vp0,1, long
term survival may be obtained. It is possible to carry
out the operation safely. For the reasons described
above, it is suggested as a indication of positive
surgery, even if it is Vv.
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